Navigation Links
CMC Biologics Completes First Stage of Expansion with Addition of Single-Use Facility
Date:8/24/2010

COPENHAGEN, Denmark and SEATTLE, Aug. 24 /PRNewswire/ -- CMC Biologics, a Contract Manufacturing Organization with manufacturing sites in Europe and the USA, today announced the completion of a new state-of-the-art disposable manufacturing facility at its Seattle, WA site.  The addition comes as part of a staged major expansion plan, which will add significant production capacity to its existing facility to accommodate a growing demand for cGMP manufacture of biopharmaceuticals.

(Logo: http://photos.prnewswire.com/prnh/20100824/SF54816LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100824/SF54816LOGO)

The multi-purpose, single-use facility will allow for early-phase clinical manufacture of a range of biopharmaceuticals, including monoclonal antibodies and other mammalian cell culture-based recombinant proteins.  CMC Biologics has partnered with Hyclone to supply the new disposable facility with processing equipment, including a 100L and two 500L single-use bioreactors (SUBs) and disposable mixers. "Disposable technology offers the advantages of increased flexibility and efficiency, decreased cross-contamination risks, and elimination of cleaning, sterilization and other change-over procedures typically associated with traditional steel tank facilities, while providing the same performance," said Andy Walker, Senior Director of Manufacturing.  "Consequently, it provides a cost-effective strategy for reducing the speed to market for many biologics."  Gustavo Mahler, President and Chief Operating Officer, added, "As process yields continue to increase through advances in protein expression, cell culture, and purification technologies, the need for costly high-volume stainless steel tank facilities will decline for some products. We believe this trend will continue to push bioprocessing toward single-use technology."  

For other products where use of disposables is not feasible, CMC Biologics continues to offer its stainless-steel clinical and commercial cGMP manufacturing facility.  They are currently increasing capacity with the addition of a second 3000L bioreactor train, identical to the existing line.  Recent client demand has prompted initial steps in the plan toward build-out of a pre-existing structure anticipated to house two 5000L commercial-ready manufacturing lines.  CMC Biologics has also increased headcount by more than 30% at its Seattle site to support the expansion.

About CMC

CMC Biologics (www.cmcbio.com) is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing services to clients around the world, from its facilities in Europe and the USA. The company specializes in custom services for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production. CMC Biologics' wide range of integrated services includes cell line development using its proprietary CHEF1® system, process development and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both stirred tank and perfusion production processes.  CMC Biologics is located in Copenhagen, Denmark, and Bothell, Washington, near Seattle.


'/>"/>
SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
2. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
3. Circle Biologics® Introduces Innovation in Medical Devices
4. Pioneer® Surgical Expands Product Specialists to Support Growing Biologics Business
5. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
6. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
7. Clive Dix Appointed as Chairman of Crescendo Biologics
8. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
9. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
10. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
11. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , January 23, 2017 Stock-Callers.com ... Pharmaceuticals Inc. (NASDAQ: CPRX ), Sophiris Bio Inc. ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: ... which turned somewhat lower in late trade on Friday, January ... dropping about 0.3%, while shares of health care companies in ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... und 3B Medical ( Winter Haven, Florida ... Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den ... Verkauf ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren ... an 3B leisten, um das in Florida ...
(Date:1/22/2017)... ABU DHABI , Saudi Arabia , January 22, 2017 ... the US and UAE ... Future , at the World Economic Forum   ... be driven by big data and powered by artificial intelligence and this trend ... that discussed the ,Hospital of the Future, at the concluding day of the ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company ... recently met with big-name retail buyers at the January ECRM Trade Show in Hilton ... uses the utmost safety standards in all of its creations to help create a ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that ... product to the United States as part of its presence to expand its market ... aims to reduce the productions of nasty toxins as a result of drinking alcohol, ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
Breaking Medicine News(10 mins):